{"id":30537,"date":"2020-05-14T08:33:52","date_gmt":"2020-05-14T08:33:52","guid":{"rendered":"https:\/\/www.gkseries.com\/blog\/?p=30537"},"modified":"2020-10-12T08:36:21","modified_gmt":"2020-10-12T08:36:21","slug":"ayush-ministry-and-csir-partners-to-conduct-trial-for-4-ayush-formulations-to-fight-coronavirus","status":"publish","type":"post","link":"https:\/\/www.gkseries.com\/blog\/ayush-ministry-and-csir-partners-to-conduct-trial-for-4-ayush-formulations-to-fight-coronavirus\/","title":{"rendered":"AYUSH Ministry and CSIR partners to conduct trial for 4 AYUSH formulations to fight coronavirus"},"content":{"rendered":"\n<p>The Ministry of AYUSH and the Council of Scientific and Industrial Research (CSIR) have partnered to validate four Ayush formulations against COVID-19. The trials are expected to start within one week. The results will be given in 3 months.<\/p>\n\n\n\n<p>The partnership is a clinical study multi-centric in different parts of the country and variable design. for this purpose, a task-force has been formed and have prepared guideline for the clinical trial<\/p>\n\n\n\n<p>Under the move, four candidates namely Ashwagandha, Yashtimadhu (Mulethi), Guduchi + Pippali (Giloy), and AYUSH-64 will be used for the trial. These drugs were invented for the treatment of malaria. Repurposing is currently going on.<\/p>\n\n\n\n<p>Under the partnership, a competitive study between Hydroxychloroquine and Ashwagandha has been planned.<\/p>\n\n\n\n<p>The four formulations will be tried as an add-on therapy and standard care for COVID-19 patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Ministry of AYUSH and the Council of Scientific and Industrial Research (CSIR) have partnered to validate four Ayush formulations against COVID-19. The trials are expected to start within one week. The results will be given in 3 months. The partnership is a clinical study multi-centric in different parts of the country and variable design. [&hellip;]<\/p>\n","protected":false},"author":404,"featured_media":30538,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1173],"tags":[],"offerexpiration":[],"class_list":["post-30537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs-may-2020"],"_links":{"self":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/users\/404"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/comments?post=30537"}],"version-history":[{"count":1,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30537\/revisions"}],"predecessor-version":[{"id":30539,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/30537\/revisions\/30539"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media\/30538"}],"wp:attachment":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media?parent=30537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/categories?post=30537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/tags?post=30537"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/offerexpiration?post=30537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}